HalioDx is a diagnostics company, previously known as Veracyte, with a focus on immuno-oncology diagnostic technologies. Since its founding in 2014, this France-based company has been dedicated to improving patient care by providing crucial answers to clinical questions. Their portfolio of immune scoring solutions, including the Immunoscore® assay, has been developed from Dr. Jérôme Galon's groundbreaking research and is a CLIA or CE-marked test for colon cancer. The company's latest €18.50M Series B investment, secured on 17 January 2018, came from a group of investors including BNP Paribas Developpement, Quest for Growth, Sofipaca, PSIM fund, Sham, and MI Care.
Through their immuno-oncology diagnostic technologies and services, HalioDx aims to contribute to precision medicine and improve treatment decisions, particularly in the current era of immuno-oncology and combination therapies. The company's Immunoscore® assay, which analyzes a tumor's immunological contexture, not only aids in daily decision-making for oncologists in cases of colon cancer but also holds potential applications in diagnosing other cancers. Overall, HalioDx plays a significant role in helping doctors make better cancer and disease diagnoses, ultimately benefitting patient care and outcomes in the health care and pharmaceutical industries.
No recent news or press coverage available for HalioDx.